Genesys Capital:

Life science venture capital

We invest in early stage life science companies that are poised to change lives for the better.

About Genesys

Expertise. Experience. Insight.

Genesys Snapshot:

  • $300M+ Raised
  • $200M+ Invested
  • 5 Funds
  • 36 Companies
  • 18 Exits

Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 36 portfolio companies and has invested more than $200M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.

Why Genesys succeeds

Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.

Stable and Proven team

Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships

Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns

We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale

We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.

Our Team

Expertise. Experience. Insight.

Deep subject knowledge, Robust industry relationships, Proven insight — meet the Genesys team.

The Genesys Team

Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.

  • Jennifer Williams

    Jennifer Williams

    Director of Finance and Operations

  • Damian Lamb

    Damian Lamb

    Co-founder, Managing Director

  • Jamie Stiff

    Jamie Stiff

    Managing Director

  • Sarah Farr

    Sarah Farr


  • Kelly Holman

    Kelly Holman

    Co-founder, Managing Director

  • Lisa Low

    Lisa Low

    Chief Financial Officer

  • Paras Sharma

    Paras Sharma


  • Elfrida Mathias

    Elfrida Mathias

    Office Manager

Our Portfolio

$200M invested
36 Companies
18 Exits

Our track record is a direct result of our approach to investment and company building.

Inversago Pharma closes US$35M Series B Financing

MONTREAL (CANADA), September 08, 2020 - Inversago Pharma Inc. today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys Capital.

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

SAN FRANCISCO, March 17, 2020 – IDbyDNA Inc., a metagenomics technology company setting a standard for detection, identification and interpretation of microorganisms and their role in human health, today announced a global strategic partnership with Illumina, Inc. (Nasdaq: ILMN), to bring comprehensive next-generation sequencing (NGS) based workflows to the global microbiology market....

Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer

TORONTO, April 04, 2019 - Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control...

Genesys Capital is pleased to announce the closing of the Series B financing of Genesys Ventures III portfolio company, Fusion Pharmaceuticals

Apr. 2, 2019 - At US$105 million, this is one of the largest private financings in the history of the Canadian Life Sciences sector. The round was co-led by OrbiMed Advisors and Varian Medical Systems...

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

SAN FRANCISCO, Feb. 19, 2019 - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018...

Fusion Pharmaceuticals Announces First Patient Dosing In A Phase 1 Clinical Trial Of [225Ac]-FPI-1434 Injection In Patients With Advanced Solid Tumors

BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019 - Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors...

Inversago Pharma receives $7 million in series A financing

MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases...

Neurological disorder biotech Aptinyx files for a $80 million IPO

May 23, 2018 – Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering...

For older news items, visit the Genesys News Archive here

Contact us

We’re listening!

Genesys Capital is located at Front St and University Ave in downtown Toronto, in the heart of the life science hub.